NLS Pharmaceutics AG announced an update to its merger and reorganization plans with Kadimastem Ltd. and NLS Pharmaceuticals (Israel) Ltd. The Fourth Amendment to the Agreement of Merger and Plan of Reorganization, dated June 5, 2025, outlines changes to the terms of the merger. Key amendments include updates to the calculation of the merger consideration, with detailed provisions for estimating closing indebtedness, cash, and adjusted cash amounts by NLS Pharmaceutics. The updated agreement reflects the collaborative efforts of the involved parties to ensure a smooth transition and integration process.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.